ClinicalTrials.gg

Diabetic Retinopathy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 779 studies for Diabetic Retinopathy across more than 10 countries. 143 are recruiting or about to start. 589 of them are mainly about Diabetic Retinopathy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,065 studies for Diabetic Retinopathy. How that becomes 778 here

This page counts the studies the registry files under Diabetic Retinopathy, and those it files under no condition that list Diabetic Retinopathythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,065Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −63List Diabetic Retinopathy as a condition, but the registry did not file them under itMost often written as “Proliferative Diabetic Retinopathy” (41), “Non-Proliferative Diabetic Retinopathy” (9), and “Non Proliferative Diabetic Retinopathy” (2). The registry filed them under other conditions only, most often Vitreous Hemorrhage (13) and Macular Edema (9).
  3. −224Match it another way52 name it in the title, 8 in a keyword, and 164 by a synonym or other text the search reads.
  4. 778The count on this page94 of them list Diabetic Retinopathy in their own words; the registry filed them under no condition.

Status

Completed
408
Status unknown
127
Recruiting
92
Terminated
51
Not yet recruiting
44
Active, not recruiting
31

Phase

Phase 2
122
Phase 3
83
Phase 4
64
Phase 1
52
Early Phase 1
9

Where

United States
267
China
83
United Kingdom
41
France
30
Italy
29
Mexico
28

Who develops what

Add Diabetic Retinopathy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 14 programs from 14 companies, 10 with this as their studies’ main aim; 5 with a live phase 3 study; 3 primary completions in the next 12 months. Compare AbbVie, AJU Pharm and Hoffmann-La Roche here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
afliberceptRecent, repeated
Evidence
  • NCT07841899 · Ollin Biosciences, Inc. · Phase 3 · live · comparator · “Aflibercept” · registered Sep 2026
  • NCT07842016 · Ollin Biosciences, Inc. · Phase 3 · live · comparator · “Aflibercept” · registered Sep 2026
  • NCT07705607 · Merck & Co., Inc · Phase 3 · live · comparator · “Aflibercept” · registered Jul 2026
  • NCT07705555 · Merck & Co., Inc · Phase 3 · live · comparator · “Aflibercept” · registered Jul 2026
  • NCT06321302 · Boehringer Ingelheim · Phase 2 · live · comparator · “Aflibercept (Eylea®) - US only” · registered Mar 2024
Regeneron Pharmaceuticals28% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2011) + 5 othersEU: Bayer (EMA 2012) + 12 others57 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24☆ Track1 live phase-3 study: NCT07235085Ocular Therapeutix, Inc.
surabgene lomparvovec☆ Track1 live phase-3 study: NCT07592273AbbVie
EYE201☆ Track2 live phase-3 studies: NCT07705607, NCT07705555Merck & Co., Inc
OLN324☆ Track2 live phase-3 studies: NCT07841899, NCT07842016Ollin Biosciences, Inc.
TNTL☆ Track1 live phase-3 study: NCT06817265Beletalent (Zhuhai) Pharmaceutical Co., Ltd

The 5 in phase 3 with the nearest primary completion, of 14 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 · Ocular Therapeutix, Inc. · Phase 3 main aimNCT07235085 A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy — primary endpoint: DRSS 2-step change status at Week 52 from baseline in the study eye (≥ 2 step improvement, ≥ 2-step worsening, < 2-step change in either direction) · 930 enrolled
  • Jul 2027 est.VX-01 · Vantage Biosciences Ltd · Phase 2 main aimNCT06770933 A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 — primary endpoint: Evaluate the efficacy of oral doses of VX-01 in subjects compared to placebo following 1 year of treatment. · 100 enrolled
  • Nov 2027 est.Oral BGE-102 · BioAge Labs, Inc. · Phase 2 main aimNCT07812090 A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema — primary endpoint: Change in Best Corrected Visual Acuity (BCVA) · 180 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Diabetic Retinopathy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiogenesis inhibitors 8 open · Corticosteroids 2 open · NSAIDs 3 · Diuretics 3

Coming up

43studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger. 8 (9%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 29 (32%) take healthy volunteers.

Recruiting studies that take each age, of 92
AgeWomenMen
107 (8%)7 (8%)
1859 (64%)59 (64%)
3077 (84%)77 (84%)
4085 (92%)85 (92%)
5087 (95%)87 (95%)
6589 (97%)89 (97%)
7585 (92%)85 (92%)
8571 (77%)71 (77%)

Across all 779 studies, recruiting or not: 15% stop at 75 or younger and 5% at 65; 11% take children; 0% are for women only and <1% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diabetic Retinopathy studies take

Of 43 phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 231 mo17–37 · 43 studies30 mo16–37 · 30 studies—
Phase 328 mo25–41 · 21 studies——
Phase 424 mo14–37 · 32 studies——
Interventional, no phase29 mo11–60 · 126 studies—36 mo12–60 · 111 studies
Observational28 mo13–61 · 90 studies—32 mo14–… · 73 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 779. Browse all 779 → or search them.